Lundbeck needed a deal, but it could struggle against strong competition in migraine.
A phase III win for Roche’s satralizumab has added to Alexion’s Soliris woes.
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
Feasibility trial success could mean a new therapy, but not for a few years yet.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.